Abstract: An injection syringe comprises a housing (1), a piston rod (6) with a non-circular cross-section and an outer thread (7), a piston rod drive which includes a piston rod guide (85) mating with the cross-section of the piston rod (6), and a nut (4) which is not axially displaceable and which mates with the thread (7) of the piston rod (6) to form a self-locking thread connection. Rotation of a dose setting element (81) causes an injection button to be screwed out to project from the housing (1). When the injection button (88) is pushed axially, such axial movement is transformed, by way of the threaded coupling, into a rotation of one of the piston drive elements (85) relative to the other one (4). A unidirectional coupling between the nut member (4) and the piston rod guide (85) allows rotation in one direction by which the piston rod (6) is transported in a distal direction.
Abstract: The present invention relates to 1,4-disubstituted piperazines of the general formula ##STR1## wherein X, Y, Z, R.sup.1, R.sup.2 and r are as defined in the detailed part of the present description or salts thereof, to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation as well as their use for the treatment of indications caused by or related to the secretion and circulation of insulin antagonising peptides, e.g. non-insulin-dependent diabetes mellitus (NIDDM) and ageing-associated obesity.
Type:
Grant
Filed:
March 18, 1999
Date of Patent:
December 21, 1999
Assignee:
Novo Nordisk A/S
Inventors:
Rolf Hohlweg, Peter Madsen, Tine Krogh J.o slashed.rgensen, Knud Erik Andersen, Brett Watson, Zdenek Polivka, Otylie Konigova, Martina Kovandova, Alexandra Silhankova, Vladimir Valenta
Abstract: The present invention relates to [1,2,4]triazolo[4,3-a]quinoxalinone compounds of the formula ##STR1## wherein R.sup.1 is POX'X" or alkyl substituted with COX' or POX'X", and X' and X" independently are hydroxy or alkoxy, and R.sup.7 is trifluoromethyl, and R.sup.6, R.sup.8 and R.sup.9 independently are piperidino, piperazinyl, morpholino, or thiomorpholino, which rings are optionally substituted with one or more of phenyl or C.sub.1-6 -alkyl and phenyl optionally being substituted with C.sub.1-6 -alkoxy; and pharmaceutically acceptable salts thereof. The compounds of the present invention are useful in the treatment of indications caused by hyperactivity of the excitatory neurotransmitters.
Abstract: Oxidation dyeing compositions for keratinous fibers which contain an oxidation enzyme derived from a strain of the genus Pyricularia, one or more dye precursors, and optionally, one or more modifiers, and methods for dyeing hair with such compositions.
Abstract: The present invention relates to rhamnogalacturonases derived from a strain of Aspergillus japonicus which (a) has a pH-optimum between 6.5 and 7.0; (b) retains at least 80% of the maximal activity throughout the pH range of 5.5-12; (c) has a temperature optimum of about 40.degree. C.; and (d) retains at least 80% of the maximal activity throughout the temperature range of 20-60.degree. C. The present invention relates to rhamnogalacturonases derived from a strain of Aspergillus aculeatus which (a) has a pH-optimum of about 5.0; (b) retains at least 80% of the maximal activity throughout the pH range of 3-6.5; (c) has a temperature optimum of about 40.degree. C.; and (d) retains at least 80% of the maximal activity throughout the temperature range of 5-50.degree. C.
Type:
Grant
Filed:
September 11, 1995
Date of Patent:
December 14, 1999
Assignee:
Novo Nordisk A/S
Inventors:
Kurt Dorreich, Henrik Dalb.o slashed.ge, Jan M.o slashed.ller Mikkelsen, Flemming Mark Christensen, Torben Halkier
Abstract: The present invention relates to enzyme preparations consisting essentially of an enzyme which has cellulytic activity and comprises a first amino acid sequence consisting of 14 amino acid residues having the following sequenceThr Arg Xaa Xaa Asp Cys Cys Xaa Xaa (SEQ ID NO:79) 1 2 3 4 5 6 7 8 9 - Xaa Cys Xaa Trp Xaa 10 11 12 13 14and a second amino acid sequence consisting of 5 amino acid residues having the following sequenceTrp Cys Cys Xaa Cys (SEQ ID NO:80) 1 2 3 4 5wherein, in position 3 of the first sequence, the amino acid is Trp, Tyr or Phe; in position 4 of the first sequence, the amino acid is Trp, Tyr or Phe; in position 8 of the first sequence, the amino acid is Arg, Lys or His; in position 9, 10, 12 and 14, respectively, of the first sequence, and in position 4 of the second sequence, the amino acid is any of the 20 naturally occurring amino acid residues with the provisos that, in the first amino acid sequence, (i) when the amino residue in position 12 is Ser, then the amino acid residue in posit
Type:
Grant
Filed:
May 21, 1996
Date of Patent:
December 14, 1999
Assignee:
Novo Nordisk A/S
Inventors:
Martin Schulein, Lene Nonboe Andersen, S.o slashed.ren Flensted Lassen, Markus Sakari Kauppinen, Lene Lange, Ruby Iium Nielsen, Michiko Ihara, Shinobu Takagi
Abstract: This invention relates to a method of reducing the pilling propensity or colour clarity of polyester fabrics and/or garments, which method comprises treating the fabric with a polyester hydrolytic enzyme and a detergent.
Type:
Grant
Filed:
July 15, 1998
Date of Patent:
December 7, 1999
Assignee:
Novo Nordisk A/S
Inventors:
Bente Konggaard Andersen, Kim Borch, Masanobu Abo, Bo Damgaard
Abstract: The present invention relates to novel peptides, pharmaceutical compositions containing them, methods for preparing the compounds, use of the compounds for preparing medicaments for treating vasomotor disturbances, in particular the peripheral vasomotor effects known as hot flushes or hot flashes, and to a method of treating vasomotor disturbances.
Type:
Grant
Filed:
July 14, 1998
Date of Patent:
December 7, 1999
Assignee:
Novo Nordisk A/S
Inventors:
Henning Th.o slashed.gersen, Kjeld Madsen, Uffe Bang Olsen, Nils Langeland Johansen, Mark Scheideler
Abstract: An isolated and purified enzyme exhibiting protease activity at a pH of 4-7 which exhibits protease activity in 5% hydrogen peroxide and which is encoded by a DNA sequence which hybridizes to a DNA sequence depicted in SEQ ID NO. 1 or 2.
Type:
Grant
Filed:
November 12, 1998
Date of Patent:
December 7, 1999
Assignee:
Novo Nordisk A/S
Inventors:
Henrik Dalb.o slashed.ge, Stephan Christgau, Lene Nonboe Andersen, Lene Venke Kofod, Markus Sakari Kauppinen, Jack Bech Nielsen, Claus Dambmann
Abstract: A method for causing gelling or increase of viscosity of an aqueous medium containing a gellable polymeric material which has functionalities with phenolic hydroxy groups, and which, in aqueous medium, is susceptible to viscosity increase or gelling in the presence of a carboxylic ester hydrolase, comprises treating the aqueous medium with: a carboxylic ester hydrolase (EC 3.1.1); and an oxidase (EC 1.10.3) and/or a peroxidase (EC 1.11.1); in the presence of an oxidizing agent suitable for use with the oxidase and/or peroxidase. Gelled products obtainable by the method may be dried or dehydrated to give products which are useful as absorbents for absorbing aqueous media, such as body fluids. In particular, gelling a pectic material obtainable from sugar beets using pectinesterase (EC 3.1.1.11) and laccase (EC 1.10.3.2).
Abstract: The present invention relates to a method of designing laccase mutants with improved stability properties, which method is based on the hitherto unknown three-dimensional structure of Coprinus cinereus laccase.
Type:
Grant
Filed:
December 18, 1997
Date of Patent:
December 7, 1999
Assignee:
Novo Nordisk A/S
Inventors:
Anders Hjelholt Pedersen, Allan Svendsen, Palle Schneider, Grethe Rasmussen, Joel Cherry
Abstract: The present invention relates to a enzyme exhibiting aminopeptidase activity, a method for producting said enzyme, and enzyme preparation containing said enzyme exhibithing aminopeptidase activity, and use of said enzyme for various industrial purposes.
Type:
Grant
Filed:
September 15, 1997
Date of Patent:
November 30, 1999
Assignee:
Novo Nordisk A/S
Inventors:
Markus Sakari Kauppinen, Joan Qi Si, Tina Spendler, Claus Dambmann, Torben Halkier, Peter Rahbek stergaard, Shamkant Anant Patkar, Kim Hansen
Abstract: The present invention relates to therapeutically active compounds of formula I ##STR1## a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful in the prevention or treatment of estrogen related diseases or syndromes.
Type:
Grant
Filed:
October 27, 1997
Date of Patent:
November 30, 1999
Assignee:
Novo Nordisk
Inventors:
Poul Jacobsen, Svend Treppendahl, Paul Stanley Bury, Anders Kanstrup, Lise Brown Christiansen
Abstract: The present invention relates to therapeutically active heterocyclic compounds, to methods for their preparation and to pharmaceutical compositions comprising the compounds. The novel compounds are useful in treating diseases in the central nervous system related to malfunctioning of the nicotinic cholinergic system.
Abstract: The present invention related to truncated GHRs of the general formula IK-(M).sub.x -A-B-(C).sub.w -D-E-(F).sub.z -G-(N).sub.y -L (I)which have the ability to stimulate release of endogenous growth hormone.
Type:
Grant
Filed:
April 18, 1997
Date of Patent:
November 23, 1999
Assignee:
Novo Nordisk A/S
Inventors:
Stefan Lutz Richter, Kjeld Madsen, Henning Thogersen, Nils Langeland Johansen, Ole Hvilsted Olsen, Peter Hongaard Andersen, Annette Hansen
Abstract: The present invention relates to isolated nucleic acid sequences encoding polypeptides having tripeptide aminopeptidase activity. The invention also relates; to nucleic acid constructs, vectors, and host cells comprising the nucleic acid sequences as well as recombinant methods for producing the polypeptides.
Abstract: The present invention relates to a method for improving the solubility of vegetable proteins. More specifically, the invention relates to methods for the solubilization of proteins in vegetable protein sources, which methods comprise treating the vegetable protein source with an efficient amount of one or more phytase enzymes, and treating the vegetable protein source with an efficient amount of one or more proteolytic enzymes. In another aspect, the invention provides animal feed additives comprising a phytase and one or more proteolytic enzymes.
Abstract: The present invention provides safe products for bleaching teeth. Oral compositions comprising at least one oxidoreductase fulfil said criteria without the presence of peroxide or with only very little peroxide present. The invention also relates to an oral care product comprising the oral composition of the invention, a method of bleaching teeth, a method for using said oral care products and the use of oxidoreductases for oxidation of teeth stains.
Type:
Grant
Filed:
February 5, 1998
Date of Patent:
November 23, 1999
Assignees:
Novo Nordisk A/S, Colgate-Palmolive Company
Inventors:
Dorrit Aaslyng, Rie Tsuchiya, Abdul Gaffar, Sahar F. Smith
Abstract: A dispenser comprising a housing forming a cylinder which is at one end closed by an end wall provided with an outlet pipe, and at the other end closed by a plunger projecting from this open end of the cylinder and being axially displaceable into the cylinder towards the end wall. The dispenser is characterized in that the outer end of the plunger is secured to the bottom of a cup shaped cap and the cylinder is provided with outwardly projecting hooks that engage the cap preventing reuse of the device.
Type:
Grant
Filed:
October 13, 1995
Date of Patent:
November 16, 1999
Assignee:
Novo Nordisk A/S
Inventors:
Kim Stengaard Petersen, Svend Elk, Hans Koster
Abstract: Contact lens are cleaned and disinfected by contacting with an enzyme that functions as a cleaning agent by degrading deposits on the lens, and with an enzyme inhibitor that inhibits remaining enzyme activity and a mild disinfecting agent. If rinsing of the lens is not carried out after cleaning and disinfecting, this procedure prevents eye damage by inhibiting remaining enzyme activity and using a mild disinfectant. Preferred enzymes are proteases such as an acidic aspartic protease, a cysteine protease, a serine protease or a metalloprotease, and preferred enzyme inhibitors function both as an inhibitor and as a mild disinfectant such as chloramine-T, chloramine-B, bacitracin or aryl boronic acids. In a preferred method, the enzyme is subtilisin A and the enzyme inhibitor and disinfectant is chloramine-T.
Type:
Grant
Filed:
February 12, 1997
Date of Patent:
November 16, 1999
Assignee:
Novo Nordisk A/S
Inventors:
Dorrit Aaslyng, Jack Bech Nielsen, Lone Kierstein Nielsen